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Research on Alzheimer’s disease (AD) 
has gone through periods of great enthu-
siasm with the view that its etiology and 
pathogenesis would be clariﬁ  ed in the near 
future. In recent years, a turning point was 
the discoveries in the nineties of mutations 
in the familial forms of the disease. A key 
development as well was the observation 
that the ε4 apolipoprotein E variant is a 
strong genetic risk factor for the late onset 
form of AD. Although these major ﬁ  ndings 
have certainly shed some light on its causes 
and progression, it is disappointing that 
we do not fully understand their involve-
ment in the disease, and the majority of 
AD cases have no clearly identiﬁ  ed risk 
factors. Furthermore, these targets have 
yet to lead to the development of effective 
drugs, although it should be acknowledged 
that several clinical trials are underway. 
Based on available data from these studies, 
it appears that these experimental thera-
pies are not likely to reverse the course 
of the disease but may perhaps stabilize it 
and/or delay its progression. To prevent 
it or postpone its onset, better diagnostic 
  methods must be developed that are suf-
ﬁ  ciently sensitive and speciﬁ  c to detect 
the disease in its earliest stages prior to 
measurable cognitive deﬁ  cits. A part of the 
problem is that AD may well be several 
different disorders with only a ﬁ  nal com-
mon endpoint, namely loss of synapses, 
neurons and aggregation of amyloid-β 
and tau, with associated pathologies and 
cognitive impairments. Once these end-
point features have been established, it 
may be too late to ﬁ  gure out the origi-
nating defects and to do much about it. 
The presumably slow progression of AD, 
starting several years and even decades 
before clinical symptoms, make it particu-
larly challenging to understand, diagnose 
early, and treat. Although several excel-
lent animal models have been developed 
for this purpose, none recapitulate all the 
aspects of AD. It is therefore not surpris-
ing that several potential therapies that 
worked in animals have been ineffective 
in clinical trials.
In summary, the major challenges in 
the ﬁ  eld are to: (1) Identify risk factors for 
the majority of the sporadic cases that are 
unrelated to apoE genotype; (2) Generate 
animal models with all the features of AD; 
(3) Detect individuals at risk prior to cogni-
tive impairment, and; (4) Develop effective 
disease-modifying therapies. Even though 
numerous outstanding scientists and clini-
cians are working on solving these obvious 
problems with some promising recent ﬁ  nd-
ings, it is important to foster involvement 
of established investigators from other 
ﬁ  elds with unconventional ideas.
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